Future Market Insights’ updated report estimates the global antibody discovery market size to grow by 2.6X over the next ten years- from US$ 8.5 billion in 2024 to US$ 21.8 billion by 2034. Global demand is anticipated to surge at 9.9% CAGR throughout the forecast period, indicating the growing importance of antibodies in modern medicine.
Phage display remains the most preferred method for antibody discovery globally, recording a CAGR of 9.7%. This can be attributed to its versatility, robustness, applicability, and other advantages.
| Attributes | Key Insights |
|---|---|
| Base Market Value (2023) | US$ 7.6 billion |
| Market Size in 2024 | US$ 8.5 billion |
| Market Revenue in 2034 | US$ 21.8 billion |
| Value-based CAGR (2024 to 2034) | 9.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Antibody therapeutics is transforming the field of medicine, offering a new ray of hope for patients with diseases that were considered untreatable previously. It has paved the way for the development of novel drug classes called therapeutic antibodies.
Growing popularity of therapeutic antibodies due to their specificity, potency, and versatility is set to boost market growth. These drugs are showing promising results in diseases like cancer and autoimmune diseases, which is fueling their demand.
Monoclonal antibodies, protein-based therapeutics, and other biologics offer several advantages over traditional small-molecule drugs. These include their greater specificity and minimal side effects. Growing interest in such biologics will create greater demand for antibody discovery technologies.
Widening application area of antibodies beyond therapeutics is another key factor boosting market growth. In the contemporary world, antibodies are being increasingly used in diagnostic applications like point-of-care testing and immunoassays. Similarly, their usage is increasing in research and biotechnology applications.
Ongoing advances in antibody technology are anticipated to result in the development of more effective treatments for several diseases. This will bode well for the market during the next ten years.
Companies are looking to develop next-generation antibody formats, including antibody-drug conjugates (ADCs), bispecific antibodies, and engineered antibodies with improved specificity and functionality. Similarly, novel technologies like AI and ML are being incorporated into discovery workflows. These factors will further boost growth of the target industry.
The global market recorded a robust CAGR of 12.4% during the historical period, with total market valuation reaching US$ 7.6 billion in 2023. In the next ten years, a CAGR of 9.9% is on the cards for the target industry, depicting a deduction of 2.5% CAGR from the historical period. By 2034, the global antibody discovery market valuation is set to reach US$ 21.8 billion.
| Historical CAGR (2019 to 2023) | 12.4% |
|---|---|
| Forecast CAGR (2024 to 2034) | 9.9% |
Historically, demand for global demand grew rapidly. This was mostly due to thriving biopharmaceutical industry and increased popularity of biologics, particularly during the COVID-19 pandemic.
Increased collaboration between some leading players and academic institutions also positively impacted the market. Similarly, a shift towards patient-centric drug development, coupled with increased demand for personalized medicine, boosted the market.
The future of antibody discovery market looks bright owing to rising cases of chronic diseases and escalating demand for novel therapies. Ongoing advances in antibody technologies will also play a key role in facilitating market growth.
Investigating new therapeutic areas such as pediatrics, neurology, and rare diseases is anticipated to uplift demand for antibody discovery through 2034. Increasing government support and favorable regulatory frameworks for developing and approving biologics like antibodies will also benefit the industry.
Advances in phage display, gene editing, and humanization techniques are facilitating the discovery process. They allow for the development of more specific and potent antibodies, which will directly impact market growth in coming years.
Principal Consultant
Growing Prevalence of Chronic and Infectious Diseases
One of the prominent factors influencing growth of the global market is the increasing incidence of chronic diseases like diabetes, cancer, and autoimmune diseases. These diseases often require novel treatments like antibodies.
Antibody-based therapies are becoming ideal tools for managing these chronic diseases due to their high effectiveness. They specifically bind to disease-causing molecules, thereby minimizing the risk of side effects. This, in turn, will create a high demand for antibody discovery services during the assessment period.
Rising Outsourcing Trends and High Investments in Research and Development
Leading biotechnology and pharmaceutical companies are rigorously investing in research and development to produce new antibody-based diagnostics and therapeutics. This is leading to the development of new technologies and platforms for antibody discovery.
Several pharmaceutical companies are also outsourcing their antibody discovery activities to prominent contract research organizations (CROs) to reduce costs and enhance their productivity. This will create lucrative growth opportunities for the target market.
There is no doubt that the antibody discovery industry has a bright future, especially in new therapeutics and diagnostics. However, it also faces certain challenges that might impact its growth.
One key challenge is the complex process of developing antibodies requiring substantial time and resources. Similarly, strict guidelines for antibody-based therapies and fierce competition are making it difficult for companies to survive in this industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section comprehensively evaluates three interrelated markets: the global antibody discovery industry, the antibody purification service market, and the drug discovery service industry. It dissects each market's distinctive characteristics, encompassing their respective CAGRs, while delving into the pivotal factors influencing their growth trajectories.
Global Antibody Discovery Market Forecast:
| Attribute | Global Market Analysis |
|---|---|
| CAGR (2024 to 2034) | 9.9% |
| Growth Factor | Escalating demand for targeted therapies like antibody-based drugs is set to boost market growth. |
| Antibody Discovery Market Trends | Key growth-shaping trends include rising interest in personalized medicine and advances in biotechnology and immunology. |
Global Antibody Purification Service Market Forecast:
| Attribute | Global Antibody Purification Service Industry Outlook |
|---|---|
| CAGR (2024 to 2034) | 11.0% |
| Growth Factor | Escalating demand for high-quality antibodies is anticipated to boost growth of the antibody purification service market. |
| Key Trends | Growing adoption of antibody-based therapeutics will benefit the market. |
Global Drug Discovery Service Market Analysis:
| Attribute | Global Drug Discovery Service Demand Outlook |
|---|---|
| CAGR (2024 to 2034) | 14.5% |
| Growth Factor | Escalating need for novel drugs to tackle diseases like cancer and rare genetic disorders is set to propel demand for drug discovery services. |
| Key Trends | A key growth influencing trend is the integration of novel technologies like AI, ML, and data analytics in drug discovery. |
The table below shows the predicted growth rates of the key countries. South Korea, Japan, and the United Kingdom are set to record high CAGRs of 12.0%, 11.4%, and 11.1%, respectively, through 2034.
| Countries | CAGR (2024 to 2034) |
|---|---|
| United States | 10.2% |
| United Kingdom | 11.1% |
| China | 10.7% |
| Japan | 11.4% |
| South Korea | 12.0% |
The table below highlights key countries’ market revenues. The United States and China are forecast to remain leading markets, with predicted valuations of US$ 3.9 billion and US$ 3.4 billion, respectively, in 2034.
| Countries | Market Revenue (2034) |
|---|---|
| United States | US$ 3.9 billion |
| United Kingdom | US$ 880.5 million |
| China | US$ 3.4 billion |
| Japan | US$ 2.4 billion |
| South Korea | US$ 1.4 billion |
The United States market is anticipated to grow at a robust CAGR of 10.2% during the forecast period, with total valuation reaching US$ 3.9 billion by 2034. This can be attributed to rising cases of cancer and burgeoning demand for targeted therapies.
There has been a spike in cancer prevalence in the United States during the last few years, and the trend is set to escalate further in the coming years. According to the Centers for Disease Control and Prevention (CDC), the total number of cancer cases in the United States is estimated to increase by 49%, reaching 2,286,300 annual cases in 2050.
The high prevalence of cancer and other chronic diseases, in turn, is set to create a greater demand for therapeutic antibodies, thereby boosting market growth. Antibody-based therapies are becoming ideal solutions for attacking specific disease cells while leaving healthy cells unhealthy.
The United States is also home to several leading biopharmaceutical companies that are rigorously investing in antibody discovery research. This will have a positive impact on the United States market share and performance throughout the forecast period.
Future Market Insight’s latest analysis estimates China's industry value to total US$ 3.4 billion by 2034. Demand in the country will probably surge at a CAGR of 10.7% throughout the forecast period.
Multiple factors are stimulating growth of China market. These include high burden of chronic diseases, increasing government initiatives and funding programs, and ongoing advances in antibody development technologies.
Amid changing lifestyles and growing geriatric population, there is a serious increase in chronic diseases like cancer and cardiovascular diseases in China. To counter this, antibody-based therapies are becoming promising treatment solutions, resulting in higher demand in the country.
The section below provides deeper insights into top segments and their respective values & shares in the global market. This information can help companies act accordingly and strengthen their presence in lucrative regions.
Based on method, the phage display segment is set to grow at 9.7% CAGR through 2034. By antibody type, the human antibody category will thrive at a CAGR of 9.5% from 2024 to 2034.
| Top Segment | Phage Display (Method) |
|---|---|
| CAGR (2024 to 2034) | 9.7% |
Phage display continues to remain the most preferred method owing to its versatility, robustness, and other advantages. The target segment accounted for a prominent market share of 47.0% in 2023 and is set to thrive at 9.7% CAGR through 2034.
Phage display has become a powerful tool for antibody discovery as it allows rapid screening of millions of antibodies. It is ideal for the creation of vast antibody libraries, allowing researchers to look for specific antibodies with optimal therapeutic characteristics.
Researchers are widely using the phage display method as it helps them to yield high-affinity antibodies ideal for diverse uses. These antibodies find applications in diagnostics, therapeutics, and research tools.
The ability of phage display technology to discover antibodies against complex targets is another key factor encouraging its adoption. Thus, it will continue to remain a key tool in modern antibody therapeutics during the assessment period.
| Top Segment | Human Antibody (Antibody Type) |
|---|---|
| CAGR (2024 to 2034) | 9.5% |
As per the latest analysis, the human antibody segment will retain its dominance in the global market through 2034, recording a CAGR of 9.5%. This can be attributed to high adoption of human antibodies in several applications due to their numerous advantages.
Human antibodies display enhanced safety profiles, enhanced efficacy, and reduced immunogenicity. As a result, their application area is widening, ranging from combating cancer and autoimmune disorders to their diagnostic applications.
Human antibodies’ compatibility with human targets improves therapeutic effectiveness while reducing the risk of adverse immune reactions. They align with the rising demand for personalized medicine.
Most regulatory bodies favor human antibodies due to their excellent safety profiles. Growing popularity of drugs developed using human antibodies will further boost growth of the target segment during the assessment period.
Several opportunities exist for companies amid burgeoning demand for antibodies for treating a wide range of diseases. To capitalize on this, top antibody discovery specialists are focusing on using advanced methods like hybridoma technology to create vast libraries of novel antibodies. Subsequently, they employ next-generation sequencing to analyze these libraries and identify promising candidates for specific biomarkers.
Automation is penetrating its roots in antibody production and purification processes, with companies looking to improve their throughput and efficiency. Top players are also adopting strategies like partnerships, collaborations, acquisitions, partnerships, and agreements to stay ahead of the curve.
Recent Developments:
The global market is set to be valued at US$ 8.5 billion in 2024.
Global demand is forecast to grow at a CAGR of 9.9% through 2034.
By 2034, the global market size is set to reach US$ 21.8 billion.
The target industry registered a CAGR of 12.4% from 2019 to 2023.
The United States is predicted to record a CAGR of 10.2% through 2034.
FMI estimates the global antibody market value to total US$ 581.42 billion by 2034.
The antibody therapy market size is set to reach US$ 824.0 billion by 2033.
It is the process of identifying new antibodies that can bind to specific target molecules like proteins.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ billion) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ billion) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Methods 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ billion) Analysis By Methods, 2019 to 2023 5.3. Current and Future Market Size Value (US$ billion) Analysis and Forecast By Methods, 2024 to 2034 5.3.1. Phage Display 5.3.2. Hybridoma 5.3.3. Others 5.4. Y-o-Y Growth Trend Analysis By Methods, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Methods, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Antibody Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ billion) Analysis By Antibody Type, 2019 to 2023 6.3. Current and Future Market Size Value (US$ billion) Analysis and Forecast By Antibody Type, 2024 to 2034 6.3.1. Humanized Antibody 6.3.2. Human Antibody 6.3.3. Chimeric Antibody 6.3.4. Murine Antibody 6.4. Y-o-Y Growth Trend Analysis By Antibody Type, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Antibody Type, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End Users 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ billion) Analysis By End User, 2019 to 2023 7.3. Current and Future Market Size Value (US$ billion) Analysis and Forecast By End User, 2024 to 2034 7.3.1. Pharmaceutical and Biotechnology Industry 7.3.2. Research Laboratory 7.3.3. Academic Laboratory 7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ billion) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ billion) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. United States 9.2.1.2. Canada 9.2.2. By Methods 9.2.3. By Antibody Type 9.2.4. By End Users 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Methods 9.3.3. By Antibody Type 9.3.4. By End Users 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Methods 10.2.3. By Antibody Type 10.2.4. By End Users 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Methods 10.3.3. By Antibody Type 10.3.4. By End Users 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Methods 11.2.3. By Antibody Type 11.2.4. By End Users 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Methods 11.3.3. By Antibody Type 11.3.4. By End Users 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Methods 12.2.3. By Antibody Type 12.2.4. By End Users 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Methods 12.3.3. By Antibody Type 12.3.4. By End Users 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Methods 13.2.3. By Antibody Type 13.2.4. By End Users 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Methods 13.3.3. By Antibody Type 13.3.4. By End Users 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Methods 14.2.3. By Antibody Type 14.2.4. By End Users 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Methods 14.3.3. By Antibody Type 14.3.4. By End Users 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of Middle East & Africa 15.2.2. By Methods 15.2.3. By Antibody Type 15.2.4. By End Users 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Methods 15.3.3. By Antibody Type 15.3.4. By End Users 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. United States 16.1.1. Market Share Analysis, 2024 16.1.1.1. By Methods 16.1.1.2. By Antibody Type 16.1.1.3. By End Users 16.2. Canada 16.2.1. Market Share Analysis, 2024 16.2.1.1. By Methods 16.2.1.2. By Antibody Type 16.2.1.3. By End Users 16.3. Brazil 16.3.1. Market Share Analysis, 2024 16.3.1.1. By Methods 16.3.1.2. By Antibody Type 16.3.1.3. By End Users 16.4. Mexico 16.4.1. Market Share Analysis, 2024 16.4.1.1. By Methods 16.4.1.2. By Antibody Type 16.4.1.3. By End Users 16.5. Germany 16.5.1. Market Share Analysis, 2024 16.5.1.1. By Methods 16.5.1.2. By Antibody Type 16.5.1.3. By End Users 16.6. United Kingdom 16.6.1. Market Share Analysis, 2024 16.6.1.1. By Methods 16.6.1.2. By Antibody Type 16.6.1.3. By End Users 16.7. France 16.7.1. Market Share Analysis, 2024 16.7.1.1. By Methods 16.7.1.2. By Antibody Type 16.7.1.3. By End Users 16.8. Spain 16.8.1. Market Share Analysis, 2024 16.8.1.1. By Methods 16.8.1.2. By Antibody Type 16.8.1.3. By End Users 16.9. Italy 16.9.1. Market Share Analysis, 2024 16.9.1.1. By Methods 16.9.1.2. By Antibody Type 16.9.1.3. By End Users 16.10. Poland 16.10.1. Market Share Analysis, 2024 16.10.1.1. By Methods 16.10.1.2. By Antibody Type 16.10.1.3. By End Users 16.11. Russia 16.11.1. Market Share Analysis, 2024 16.11.1.1. By Methods 16.11.1.2. By Antibody Type 16.11.1.3. By End Users 16.12. Czech Republic 16.12.1. Market Share Analysis, 2024 16.12.1.1. By Methods 16.12.1.2. By Antibody Type 16.12.1.3. By End Users 16.13. Romania 16.13.1. Market Share Analysis, 2024 16.13.1.1. By Methods 16.13.1.2. By Antibody Type 16.13.1.3. By End Users 16.14. India 16.14.1. Market Share Analysis, 2024 16.14.1.1. By Methods 16.14.1.2. By Antibody Type 16.14.1.3. By End Users 16.15. Bangladesh 16.15.1. Market Share Analysis, 2024 16.15.1.1. By Methods 16.15.1.2. By Antibody Type 16.15.1.3. By End Users 16.16. Australia 16.16.1. Market Share Analysis, 2024 16.16.1.1. By Methods 16.16.1.2. By Antibody Type 16.16.1.3. By End Users 16.17. New Zealand 16.17.1. Market Share Analysis, 2024 16.17.1.1. By Methods 16.17.1.2. By Antibody Type 16.17.1.3. By End Users 16.18. China 16.18.1. Market Share Analysis, 2024 16.18.1.1. By Methods 16.18.1.2. By Antibody Type 16.18.1.3. By End Users 16.19. Japan 16.19.1. Market Share Analysis, 2024 16.19.1.1. By Methods 16.19.1.2. By Antibody Type 16.19.1.3. By End Users 16.20. South Korea 16.20.1. Market Share Analysis, 2024 16.20.1.1. By Methods 16.20.1.2. By Antibody Type 16.20.1.3. By End Users 16.21. GCC Countries 16.21.1. Market Share Analysis, 2024 16.21.1.1. By Methods 16.21.1.2. By Antibody Type 16.21.1.3. By End Users 16.22. South Africa 16.22.1. Market Share Analysis, 2024 16.22.1.1. By Methods 16.22.1.2. By Antibody Type 16.22.1.3. By End Users 16.23. Israel 16.23.1. Market Share Analysis, 2024 16.23.1.1. By Methods 16.23.1.2. By Antibody Type 16.23.1.3. By End Users 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Methods 17.3.3. By Antibody Type 17.3.4. By End Users 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Danaher Corporation 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Eurofins Scientific 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Evotec 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Twist Bioscience 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Charles River Laboratories 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Genscript Technology Corporation 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Biocytogen 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Sartorius AG 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Fairjourney Biologics S.A 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Creative Biolabs 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Antibody Discovery Market
